Zytig Treatment Prolongs Survival in Advanced Prostate Cancer
Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC)
Zytiga is an oral targeted agent that blocks the production of androgens (male hormones such as testosterone) not only by the testes, but also by the adrenal glands and the tumor itself. It was initially approved in April 2011 for use in patients whose prostate cancer progressed after chemotherapy.
About the LATITUDE Study
The LATITUDE clinical study treated 1199 men with newly diagnosed, high-risk metastatic prostate cancer who had not previously received ADT. All patients had at least two of three risk factors: Gleason score (a measure of tumor grade) of 8 or more, 3 or more bone metastases, or 3 or more visceral metastases (spread to other organs in certain areas of the body, such as the liver). Individuals were treated with ADT plus Zytiga and prednisone, or ADT alone and directly compared.
After a median follow-up of 51.8 months a final analysis of the trial has been performed and published in Lancet Oncology. The overall survival is significantly longer for patients receiving Zytig/ADT/prednisone. Zytig treated patients survived on average 53 months compared to 36.5 months for ADT alone.
Side effects attributable to Zytig include hypertension and hypokalemia.
The combination of Zytig plus prednisone with can now be considered standard of care in patients with high-risk CSPC.
Lancet Oncol. 2019 Apr 12. Epub ahead of print.
Copyright © 2020 CancerConnect. All Rights Reserved.